The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT)
-
- Christian H. Geisler
- Rigshospitalet, Copenhagen, Denmark;
-
- Arne Kolstad
- Norwegian Radium Hospital, Oslo, Norway;
-
- Anna Laurell
- Uppsala University Hospital, Uppsala, Sweden;
-
- Riikka Räty
- Helsinki University Central Hospital, Helsinki, Finland;
-
- Mats Jerkeman
- Lund University Hospital, Lund, Sweden;
-
- Mikael Eriksson
- Lund University Hospital, Lund, Sweden;
-
- Marie Nordström
- Karolinska Institutet, Stockholm, Sweden;
-
- Eva Kimby
- Karolinska Institutet, Stockholm, Sweden;
-
- Anne Marie Boesen
- Aarhus University Hospital, Aarhus, Denmark;
-
- Herman Nilsson-Ehle
- Sahlgrenska Hospital, Gothenburg, Sweden; and
-
- Outi Kuittinen
- Oulu University Hospital, Oulu, Finland
-
- Grete F. Lauritzsen
- Norwegian Radium Hospital, Oslo, Norway;
-
- Elisabeth Ralfkiær
- Rigshospitalet, Copenhagen, Denmark;
-
- Mats Ehinger
- Lund University Hospital, Lund, Sweden;
-
- Christer Sundström
- Uppsala University Hospital, Uppsala, Sweden;
-
- Jan Delabie
- Norwegian Radium Hospital, Oslo, Norway;
-
- Marja-Liisa Karjalainen-Lindsberg
- Helsinki University Central Hospital, Helsinki, Finland;
-
- Peter Brown
- Rigshospitalet, Copenhagen, Denmark;
-
- Erkki Elonen
- Helsinki University Central Hospital, Helsinki, Finland;
この論文をさがす
説明
<jats:title>Abstract</jats:title> <jats:p>Mantle cell lymphoma (MCL) has a heterogeneous clinical course. The recently proposed Mantle Cell Lymphoma International Prognostic Index (MIPI) predicted the survival of MCL better than the International Prognostic Index in MCL patients treated with conventional chemotherapy, but its validity in MCL treated with more intensive immunochemotherapy has been questioned. Applied here to 158 patients of the Nordic MCL2 trial of first-line intensive immunochemotherapy followed by high-dose chemotherapy and autologous stem cell transplantation, the MIPI and the simplified MIPI (s-MIPI) predicted survival significantly better (P < .001) than the International Prognostic Index (P > .004). Both the MIPI and the s-MIPI mainly identified 2 risk groups, low and intermediate versus high risk, with the more easily applied s-MIPI being just as powerful as the MIPI. The MIPIB (biological), incorporating Ki-67 expression, identified almost half of the patients as high risk. We suggest that also a simplified MIPIB is feasible. This trial was registered at www.isrctn.org as #ISRCTN 87866680.</jats:p>
収録刊行物
-
- Blood
-
Blood 115 (8), 1530-1533, 2010-02-25
American Society of Hematology
